Free Trial

Madrigal Pharmaceuticals (MDGL) Competitors

Madrigal Pharmaceuticals logo
$306.76 -6.64 (-2.12%)
Closing price 04:00 PM Eastern
Extended Trading
$313.25 +6.49 (+2.12%)
As of 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MDGL vs. BIIB, UTHR, INCY, NBIX, EXEL, BMRN, EXAS, HALO, IONS, and RGEN

Should you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), and Repligen (RGEN). These companies are all part of the "biotechnology" industry.

Madrigal Pharmaceuticals vs. Its Competitors

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Madrigal Pharmaceuticals has a beta of -1.05, suggesting that its share price is 205% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500.

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 21.5% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Biogen has a net margin of 15.07% compared to Madrigal Pharmaceuticals' net margin of -123.38%. Biogen's return on equity of 14.03% beat Madrigal Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Madrigal Pharmaceuticals-123.38% -50.54% -37.19%
Biogen 15.07%14.03%8.32%

Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Madrigal Pharmaceuticals$180.13M37.81-$465.89M-$18.05-17.00
Biogen$9.68B1.98$1.63B$10.1312.93

Madrigal Pharmaceuticals presently has a consensus target price of $420.63, suggesting a potential upside of 37.12%. Biogen has a consensus target price of $186.37, suggesting a potential upside of 42.29%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than Madrigal Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Madrigal Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89
Biogen
0 Sell rating(s)
21 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.34

In the previous week, Biogen had 32 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 50 mentions for Biogen and 18 mentions for Madrigal Pharmaceuticals. Biogen's average media sentiment score of 0.72 beat Madrigal Pharmaceuticals' score of 0.39 indicating that Biogen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Madrigal Pharmaceuticals
10 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biogen
23 Very Positive mention(s)
4 Positive mention(s)
12 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Biogen beats Madrigal Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Madrigal Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDGL vs. The Competition

MetricMadrigal PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$6.96B$2.44B$5.57B$9.43B
Dividend YieldN/A1.80%4.05%3.99%
P/E Ratio-17.009.1428.0520.07
Price / Sales37.81741.26451.48104.76
Price / CashN/A166.9336.1958.45
Price / Book8.875.168.605.83
Net Income-$465.89M$30.99M$3.24B$258.27M
7 Day Performance-11.08%4.96%4.63%3.98%
1 Month Performance8.40%16.68%12.93%14.89%
1 Year Performance9.74%0.32%35.40%19.29%

Madrigal Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDGL
Madrigal Pharmaceuticals
4.2834 of 5 stars
$306.76
-2.1%
$420.63
+37.1%
+9.2%$6.96B$180.13M-17.0090News Coverage
Insider Trade
BIIB
Biogen
4.9307 of 5 stars
$122.68
-1.8%
$186.37
+51.9%
-43.6%$18.31B$9.68B12.117,605Analyst Upgrade
UTHR
United Therapeutics
4.9831 of 5 stars
$293.12
+0.4%
$383.08
+30.7%
-10.4%$13.17B$2.88B11.651,305Positive News
Upcoming Earnings
INCY
Incyte
4.5937 of 5 stars
$67.38
-0.7%
$74.47
+10.5%
+5.7%$13.14B$4.24B99.792,617Upcoming Earnings
Insider Trade
NBIX
Neurocrine Biosciences
4.4834 of 5 stars
$131.83
-0.1%
$163.87
+24.3%
-8.6%$13.07B$2.36B44.751,800Upcoming Earnings
Analyst Forecast
EXEL
Exelixis
4.8352 of 5 stars
$44.26
-0.5%
$45.28
+2.3%
+96.8%$12.13B$2.17B20.591,147Positive News
Upcoming Earnings
Analyst Forecast
BMRN
BioMarin Pharmaceutical
4.9869 of 5 stars
$56.56
-1.3%
$93.78
+65.8%
-30.6%$10.99B$2.85B21.033,040Analyst Forecast
Analyst Revision
EXAS
Exact Sciences
4.7667 of 5 stars
$48.36
-4.2%
$70.50
+45.8%
+3.5%$9.52B$2.76B0.007,000Positive News
HALO
Halozyme Therapeutics
4.8177 of 5 stars
$55.92
-0.9%
$62.70
+12.1%
+5.9%$6.96B$1.02B14.87390News Coverage
Positive News
IONS
Ionis Pharmaceuticals
4.5788 of 5 stars
$41.55
-0.5%
$57.13
+37.5%
-17.1%$6.65B$705M-13.901,069News Coverage
Positive News
Upcoming Earnings
Analyst Revision
RGEN
Repligen
4.624 of 5 stars
$114.80
-1.2%
$170.75
+48.7%
-11.9%$6.53B$634.44M73.111,778Upcoming Earnings
Analyst Upgrade
Analyst Revision

Related Companies and Tools


This page (NASDAQ:MDGL) was last updated on 7/23/2025 by MarketBeat.com Staff
From Our Partners